Exploring the roles of the Cdc2-like kinases in cancers

Alexis C Blackie; Daniel J Foley

doi:10.1016/j.bmc.2022.116914

Exploring the roles of the Cdc2-like kinases in cancers

Bioorg Med Chem. 2022 Sep 15:70:116914. doi: 10.1016/j.bmc.2022.116914. Epub 2022 Jul 6.

Authors

Alexis C Blackie¹, Daniel J Foley²

Affiliations

¹ School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand.
² School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand. Electronic address: daniel.foley@canterbury.ac.nz.

PMID: 35872347
DOI: 10.1016/j.bmc.2022.116914

Abstract

The Cdc2-like kinases (CLKs 1-4) are involved in regulating the alternative splicing of a variety of genes. Their activity contributes to important cellular processes such as proliferation, differentiation, apoptosis, migration, and cell cycle regulation. Abnormal expression of CLKs can lead to cancers; therefore, pharmacological inhibition of CLKs may be a useful therapeutic strategy. This review summarises what is known about the roles of each of the CLKs in cancerous cells, as well as the effects of relevant small molecule CLK inhibitors.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Alternative Splicing
Humans
Neoplasms* / drug therapy
Phosphorylation
Protein Serine-Threonine Kinases
Protein-Tyrosine Kinases*

Substances

Protein-Tyrosine Kinases
Protein Serine-Threonine Kinases